- Home
- VRAX vs ENVB Comparison
VRAX vs ENVB Comparison
Compare VRAX & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- ENVB
- Stock Information
- Founded
- VRAX 2013
- ENVB 1994
- Country
- VRAX United Kingdom
- ENVB United States
- Employees
- VRAX N/A
- ENVB N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- VRAX Health Care
- ENVB Health Care
- Exchange
- VRAX Nasdaq
- ENVB Nasdaq
- Market Cap
- VRAX 2.8M
- ENVB 3.0M
- IPO Year
- VRAX 2022
- ENVB N/A
- Fundamental
- Price
- VRAX $0.52
- ENVB $6.28
- Analyst Decision
- VRAX Strong Buy
- ENVB Strong Buy
- Analyst Count
- VRAX 1
- ENVB 1
- Target Price
- VRAX $3.00
- ENVB $10.00
- AVG Volume (30 Days)
- VRAX 278.3K
- ENVB 121.7K
- Earning Date
- VRAX 01-01-0001
- ENVB 11-13-2025
- Dividend Yield
- VRAX N/A
- ENVB N/A
- EPS Growth
- VRAX N/A
- ENVB N/A
- EPS
- VRAX N/A
- ENVB N/A
- Revenue
- VRAX $6,331.00
- ENVB N/A
- Revenue This Year
- VRAX $217,274.83
- ENVB N/A
- Revenue Next Year
- VRAX N/A
- ENVB N/A
- P/E Ratio
- VRAX N/A
- ENVB N/A
- Revenue Growth
- VRAX N/A
- ENVB N/A
- 52 Week Low
- VRAX $0.52
- ENVB $5.62
- 52 Week High
- VRAX $3.20
- ENVB $96.30
- Technical
- Relative Strength Index (RSI)
- VRAX 29.78
- ENVB 73.15
- Support Level
- VRAX $0.57
- ENVB $5.62
- Resistance Level
- VRAX $0.64
- ENVB $8.61
- Average True Range (ATR)
- VRAX 0.04
- ENVB 0.51
- MACD
- VRAX -0.01
- ENVB 0.62
- Stochastic Oscillator
- VRAX 0.06
- ENVB 71.02
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.